MAbSilico is a premier TechBio company dedicated to developing and providing cutting-edge AI-based solutions for antibody drug design and discovery. They empower biotech and pharmaceutical companies to significantly leverage antibody discovery risks by providing high-potential computational candidates in just a matter of days. These candidates are meticulously designed and characterized in silico and subsequently validated with state-of-the-art biological technologies, ensuring a seamless transition from digital modeling to laboratory success. By combining sophisticated 3D modeling, complex interaction simulations, and advanced linear sequence analysis, MAbSilico defines antibody drug candidates through a rigorous assessment of their epitope, affinity, off-target risk, cross-species reactivity, and developability, ensuring they are fully prepared for biological activity evaluation.

Beyond their services, MAbSilico is advancing its own innovative discovery pipeline available for out-licensing, featuring high-quality leads in monoclonal, bispecific, and antibody-drug conjugate modalities. Their commitment to global innovation is reflected in an aggressive US development strategy, where they are actively seeking strategic partners to extend the deployment of their antibody design platform across the North American ecosystem. This international reach is further strengthened by their exclusive partnership with Yntoab to serve the Korean market and a landmark collaboration with Sartorius. The Sartorius partnership offers a comprehensive end-to-end solution that bridges the gap between lead candidate design and lead candidate production, including integrated cell line development to accelerate the path to clinical trials.

Furthermore, MAbSilico utilizes advanced NLP technologies to gather exhaustive information about antibodies and their targets from global databases, ensuring robust competitive landscape analysis and the freedom to operate for all computationally designed candidates. Through these integrated technologies and global alliances, MAbSilico transforms the traditional discovery process into a predictive, high-velocity engine for the next generation of immunotherapy.

DeepLife is a techbio company advancing drug positioning through artificial intelligence and digital twins of human cell types.

Its platform, TwinCell, simulates cell-type-specific behaviour by integrating over 1 billion harmonized single-cell omics data points with causal AI, enabling more precise target identification, drug repositioning and disease understanding.

DeepLife applies this technology across autoimmune, neurodegenerative and cardio metabolic diseases among others. It partners with pharmaceutical and biotech companies on asset de-risking, indication expansion and disease relevant assessment. The company has established strategic collaborations including with Biersdorf in skin disease and aging.

DeepLife leverages cell-type-specific digital twin models to pinpoint the most relevant disease indications for any therapeutic compound. At the core is TwinCell – a large-scale causal model of cell biology that identifies the molecular drivers of disease and how to reverse them. TwinCell combines this insight with large scale single cell multi omics data to build precise models of human cell types and their regulatory networks.

These digital twins replicate real cellular behaviour, predicting preclinical outcomes and enabling researchers to explore disease mechanisms in silico. This approach uncovers how compounds act at the cell-type level, enhancing target validation, biomarker discovery and indication selection.

Applied across the drug development lifecycle, TwinCell accelerates decision making, reduces risk and improves translational relevance. It supports novel target discovery, asset de-risking, indication expansion and pipeline prioritization through strategic collaborations with pharmaceutical and biotech partners.